DK2961426T3 - Behandling af sygdomme i centralnervesystemet ved intranasal indgivelse af immunoglobulin g - Google Patents
Behandling af sygdomme i centralnervesystemet ved intranasal indgivelse af immunoglobulin g Download PDFInfo
- Publication number
- DK2961426T3 DK2961426T3 DK14714815T DK14714815T DK2961426T3 DK 2961426 T3 DK2961426 T3 DK 2961426T3 DK 14714815 T DK14714815 T DK 14714815T DK 14714815 T DK14714815 T DK 14714815T DK 2961426 T3 DK2961426 T3 DK 2961426T3
- Authority
- DK
- Denmark
- Prior art keywords
- immunoglobulin
- diseases
- treatment
- nervous system
- central nervous
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940027941 immunoglobulin g Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361769673P | 2013-02-26 | 2013-02-26 | |
US201361862814P | 2013-08-06 | 2013-08-06 | |
PCT/US2014/018426 WO2014134070A1 (en) | 2013-02-26 | 2014-02-25 | Treatment of central nervous system disorders by intranasal administration of immunoglobulin g |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2961426T3 true DK2961426T3 (da) | 2019-12-02 |
Family
ID=50424697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14714815T DK2961426T3 (da) | 2013-02-26 | 2014-02-25 | Behandling af sygdomme i centralnervesystemet ved intranasal indgivelse af immunoglobulin g |
Country Status (13)
Country | Link |
---|---|
US (5) | US9556260B2 (da) |
EP (2) | EP2961426B1 (da) |
JP (1) | JP6379113B2 (da) |
AU (2) | AU2014223679B2 (da) |
DK (1) | DK2961426T3 (da) |
ES (1) | ES2759226T3 (da) |
HR (1) | HRP20192111T1 (da) |
HU (1) | HUE046752T2 (da) |
LT (1) | LT2961426T (da) |
PL (1) | PL2961426T3 (da) |
PT (1) | PT2961426T (da) |
SI (1) | SI2961426T1 (da) |
WO (1) | WO2014134070A1 (da) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150100042A1 (en) * | 2013-10-07 | 2015-04-09 | Impel Neuropharma Inc. | Muroid Family Nasal Device |
EP3129013A1 (en) * | 2014-04-10 | 2017-02-15 | Crowley, Patrick | Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders |
US11844859B2 (en) | 2017-08-20 | 2023-12-19 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
CA3071552A1 (en) | 2017-08-20 | 2019-02-28 | Formulex Pharma Innovations Ltd. | Dry powder compositions for intranasal delivery |
WO2020163815A1 (en) * | 2019-02-07 | 2020-08-13 | Innomed Technologies, Inc. | Ivig treatments for bell's palsy |
US20230181027A1 (en) * | 2019-06-28 | 2023-06-15 | Mayo Foundation For Medical Education And Research | Methods and materials for treating neuromyelitis optica spectrum diseases |
JP2022544414A (ja) * | 2019-08-13 | 2022-10-18 | アルティミューン インコーポレーティッド | 治療剤の有効性及びその投与の経路 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE348942B (da) | 1970-06-02 | 1972-09-18 | Statens Bakteriologiska Labor | |
US5624898A (en) | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
AU693306B2 (en) | 1995-01-23 | 1998-06-25 | Direct-Haler A/S | An inhaler |
IL144988A0 (en) | 1999-03-03 | 2002-06-30 | Optinose As | Nasal delivery device |
US6585957B1 (en) | 2000-01-25 | 2003-07-01 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
US20070254889A1 (en) * | 2001-04-23 | 2007-11-01 | Lee-Way Jin | Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease |
JP2005508338A (ja) | 2001-10-04 | 2005-03-31 | プロテイン セラピューティクス、インク. | 免疫性疾患を処置するためのガンマグロブリンの使用 |
US20040101909A1 (en) | 2002-08-20 | 2004-05-27 | Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 | Purification of polyreactive autoantibodies and uses thereof |
NZ581205A (en) | 2005-02-23 | 2011-06-30 | Alza Corp | Intranasal administration of active agents to the central nervous system |
US20090136505A1 (en) | 2005-02-23 | 2009-05-28 | Johanna Bentz | Intranasal Administration of Active Agents to the Central Nervous System |
WO2007074880A1 (ja) * | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
PT1981540E (pt) | 2006-01-30 | 2013-05-07 | Grifols Therapeutics Inc | Método de tratamento e profilaxia de doenças relacionadas com a deposição de amilóides utilizando igm |
CA2642473A1 (en) * | 2006-02-15 | 2007-08-23 | Ramot At Tel Aviv University | Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain |
JP2011504163A (ja) | 2007-06-08 | 2011-02-03 | ヘルスパートナーズ リサーチ ファウンデーション | 中枢神経系への治療化合物の標的化を高めるための薬学的組成物および方法 |
AU2009222199A1 (en) * | 2008-02-29 | 2009-09-11 | Baxter Healthcare S.A. | Anti-amyloid beta activity of intravenous immunoglobulin (IVIG) in vitro |
US8622993B2 (en) | 2009-12-18 | 2014-01-07 | Healthpartners Research Foundation | Device and method for delivering therapeutic substances to the maxillary sinus of a patient |
CA2788863C (en) * | 2010-02-04 | 2020-07-07 | Reinhard Franz Bolli | Immunoglobulin preparation |
WO2011150284A2 (en) * | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
-
2014
- 2014-02-25 EP EP14714815.9A patent/EP2961426B1/en active Active
- 2014-02-25 HU HUE14714815A patent/HUE046752T2/hu unknown
- 2014-02-25 SI SI201431417T patent/SI2961426T1/sl unknown
- 2014-02-25 JP JP2015559285A patent/JP6379113B2/ja active Active
- 2014-02-25 EP EP19197257.9A patent/EP3597220A1/en not_active Withdrawn
- 2014-02-25 PL PL14714815T patent/PL2961426T3/pl unknown
- 2014-02-25 PT PT147148159T patent/PT2961426T/pt unknown
- 2014-02-25 US US14/189,981 patent/US9556260B2/en active Active
- 2014-02-25 DK DK14714815T patent/DK2961426T3/da active
- 2014-02-25 AU AU2014223679A patent/AU2014223679B2/en active Active
- 2014-02-25 ES ES14714815T patent/ES2759226T3/es active Active
- 2014-02-25 WO PCT/US2014/018426 patent/WO2014134070A1/en active Application Filing
- 2014-02-25 LT LTEP14714815.9T patent/LT2961426T/lt unknown
-
2016
- 2016-10-26 US US15/335,027 patent/US10144776B2/en active Active
-
2018
- 2018-10-19 US US16/165,993 patent/US20190055307A1/en not_active Abandoned
- 2018-11-08 AU AU2018260883A patent/AU2018260883B2/en not_active Expired - Fee Related
-
2019
- 2019-11-25 HR HRP20192111TT patent/HRP20192111T1/hr unknown
-
2020
- 2020-12-14 US US17/121,553 patent/US11851481B2/en active Active
-
2023
- 2023-11-13 US US18/507,265 patent/US20240117025A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20140242067A1 (en) | 2014-08-28 |
US20170044244A1 (en) | 2017-02-16 |
AU2014223679B2 (en) | 2018-11-29 |
US11851481B2 (en) | 2023-12-26 |
JP2016512490A (ja) | 2016-04-28 |
US20210101967A1 (en) | 2021-04-08 |
US20190055307A1 (en) | 2019-02-21 |
AU2018260883A1 (en) | 2018-11-29 |
US10144776B2 (en) | 2018-12-04 |
LT2961426T (lt) | 2019-12-27 |
AU2014223679A1 (en) | 2015-09-24 |
SI2961426T1 (sl) | 2020-01-31 |
EP2961426A1 (en) | 2016-01-06 |
HUE046752T2 (hu) | 2020-03-30 |
EP2961426B1 (en) | 2019-10-30 |
EP3597220A1 (en) | 2020-01-22 |
US20240117025A1 (en) | 2024-04-11 |
US9556260B2 (en) | 2017-01-31 |
PL2961426T3 (pl) | 2020-02-28 |
AU2018260883B2 (en) | 2020-08-06 |
HRP20192111T1 (hr) | 2020-03-20 |
WO2014134070A1 (en) | 2014-09-04 |
PT2961426T (pt) | 2019-12-09 |
ES2759226T3 (es) | 2020-05-08 |
JP6379113B2 (ja) | 2018-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTC2785706I2 (lt) | Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui | |
DK2983787T3 (da) | Fremgangsmåde til behandling af posttraumatisk stresssygdom | |
DK3811943T3 (da) | Forbindelse til anvendelse til behandling af øjenlidelser | |
DK2919796T3 (da) | Brug af akkermansia til behandling af stofskiftesygdomme | |
DK2830662T3 (da) | Fremgangsmåder til behandlng af hårtabsforstyrrelser | |
DK3076967T3 (da) | Fremgangsmåder til behandling af residuelle symptomer på skizofreni | |
DK2954051T3 (da) | Modificeret kapsid til genoverførsel til behandling af nethinden | |
DK2961410T3 (da) | Anvendelse af pyrazolopyrimidinderivater til behandlingen af pi3k relaterede lidelser | |
DK2968208T3 (da) | Behandling af kataplexi | |
DK3024497T3 (da) | Fremgangsmåder og præparater til behandling af hjernesygdomme | |
DK3033086T3 (da) | Kombinationsterapi til behandling af cancer | |
DK2895156T3 (da) | Fremgangsmåde til fremstilling af terapeutiske nanopartikler | |
DK2981255T3 (da) | Terapeutiske anvendelser af empagliflozin | |
DK3321276T3 (da) | Fusionsproteiner til behandling af metaboliske lidelser | |
DK2964315T3 (da) | System til behandling af neuromotorisk dysfunktion | |
DK2852391T3 (da) | Systemer til behandling af lungeinfektioner | |
DK3311824T3 (da) | Cd47 målrettede terapier til behandlingen af infektionssygdomme | |
DK2981269T3 (da) | Behandling af stofskifteforstyrrelser hos hestedyr | |
DK3626270T3 (da) | Behandling af kardiovaskulære sygdomme | |
DK3054976T3 (da) | Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose | |
DK2747763T3 (da) | (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser | |
DK2961426T3 (da) | Behandling af sygdomme i centralnervesystemet ved intranasal indgivelse af immunoglobulin g | |
DK2838539T3 (da) | Østrogenderivater til anvendelse i behandlingen af neurologiske forstyrrelser | |
DK3003366T3 (da) | På hinanden følgende overlappende peptider til behandling af allergi overfor husstøvmider | |
DK2961378T3 (da) | Fremgangsmåder til behandlingen af mitochondrisk sygdom |